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Abstract
Ovarian sex cord-stromal tumors (SCST) are uncommon tumors accounting 
for approximately 8% of all ovarian malignancies. By far, the most common are 
granulosa cell tumors (GCT) which represent approximately 90% of SCST. SCST 
are also found in the hereditary syndromes: Peutz-Jeghers syndrome, Ollier disease 
and Maffucci syndrome, and DICER1 syndrome. Key genomic and genetic events 
contributing to their pathogenesis have been the focus of recent studies. Most of the 
genomic studies have been limited to GCT which have identified a number of recur-
ring chromosomal abnormalities (monosomy and trisomy), although their contri-
bution to pathogenesis remains unclear. Recurrent DICER1 mutations are reported 
in non-hereditary cases of Sertoli cell and Sertoli–Leydig cell tumors (SLCT), while 
recurrent somatic mutations in both the juvenile (jGCT) and adult forms of GCT 
(aGCT) have also been reported. Approximately 30% of jGCT contain a somatic 
mutation in the gsp oncogene, while a further 60% have activating mutations or 
duplications in the AKT gene. For aGCT, a well characterized mutation in the 
FOXL2 transcription factor (FOXL2 C134W) is found in the majority of tumors 
(primary and recurrent), arguably defining the disease. A further mutation in the 
human telomerase promoter appears to be an important driver for recurrent disease 
in aGCT. However, despite several studies involving next generation sequencing, 
the molecular events that determine the stage, behavior and prognosis of aGCT still 
remain to be determined. Further, there is a need for these studies to be expanded to 
other SCST in order to identify potential targets for personalized medicine.
Keywords: ovarian cancer, ovary, sex cord stromal tumor, Granulosa cell tumor, 
FOXL2 C134W, TERT, Sertoli-Leydig cell tumor, DICER1 mutation, transcriptomics, 
Whole Exome Sequencing
1. Introduction
Ovarian sex cord-stromal tumors (SCST) are a clinically significant group of 
uncommon neoplasms that represent approximately 8% of ovarian cancers. They 
are thought to arise primarily from the gonadal sex-cord (granulosa and Sertoli 
cells) and/or gonadal stromal cells (theca cells) [1]. Malignant ovarian tumors 
are a group of morphologically, genetically and functionally distinct diseases, 
but associated with the same organ, the ovary. Epithelial ovarian cancers (EOC) 
Ovarian Cancer - Updates in Tumour Biology and Therapeutics
2
represent the majority of ovarian cancers (accounting for 85–90%), the other two 
primary classifications are the SCST and the rarer germ cell tumors [2]. Ovarian 
SCST are primarily classified histologically as granulosa cell tumors (GCT), Sertoli 
stromal tumors and SCST of mixed or unclassified cell type, theca-fibroma. In the 
most recent World Health Organization (WHO) classification of female reproduc-
tive tract tumors, SCSTs are separated into pure stromal, pure sex cord and mixed 
SCST [3] with the sub-classifications of these groups as shown in Table 1. GCT are 
the most common accounting for approximately 90% of all malignant SCST. The 
clinical and molecular features of GCT has been extensively reviewed by Jamieson 
and Fuller [2]. Although recurrent and advanced stage GCT are associated with a 
very high mortality [2], they remain a relatively neglected subset of tumors. The 
high mortality rate of advanced disease has not been helped by the tendency to 
group these ovarian cancers with EOC, and apply treatment regimens that are based 
on therapeutic approaches for EOC, rather than tailoring treatment to the specific 
SCST [2]. Thus, understanding the genetics and hence the biology of these distinct 
tumors has an immediacy beyond just understanding tumor biology, with targeted 
therapeutics urgently needed for women with SCST. In this review we will provide 
an overview of studies that explore insights into the genetics and genomics of these 
tumors, with the aim to seek to identify key unanswered questions.
2. Ovarian SCST: clinical, histology and functional aspects
2.1 Granulosa cell tumors
Granulosa cell tumors (GCT) of the ovary are the most common type of SCST, 
accounting for approximately 5% of all ovarian cancers [4]. GCT are subdivided 
into two types: the more common adult (aGCT) and the rarer juvenile (jGCT) 
form. The jGCT subtype represents approximately 5% of all GCT. The two subtypes 
have different etiologies, and classification for either are not based on age alone as 
either tumor type can occur at any age. GCT arise from the granulosa cells (GC) of 
the ovarian follicle, and exhibit many features of normal GC, including expression 
A. Granulosa-stromal cell tumors
1. Granulosa cell tumor
a. Adult granulosa cell tumor
b. Juvenile granulosa cell tumor






B. Sertoli–Leydig cell tumors
1. Well-differentiated
a. Sertoli cell tumor
b. Sertoli cell tumor with lipid storage
c. Sertoli–Leydig cell tumor (tubular adenoma with Leydig cells)
2. Moderately differentiated
3. Poorly differentiated (sarcomatoid)
4. Retiform with heterologous elements
C. Gynandroblastoma
D. Unclassified
aAdapted from Scully [1] and the 2014 WHO classification [3].
Table 1. 
Histological classification of ovarian sex cord-stromal tumorsa.
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of the follicle stimulating hormone (FSH) receptor gene, estrogen synthesis, ERβ 
expression, inhibin subunit expression with synthesis of biologically active inhibin, 
and anti-Müllerian hormone (AMH) expression [2]. Their presentation may include 
endocrine manifestations such as features of estrogen excess in prepubertal girls and 
postmenopausal women. The gonadal peptides inhibin and anti- Müllerian hormone 
(AMH) can be used in diagnosis and more specifically as tumor markers [2]. Studies 
from our laboratory as well as those of others have examined gene expression and 
signaling pathways involved in GC development, and have provided compelling 
support that not only are GC the cell type of origin for GCT, but that GCT also have 
consistent features with proliferating GC of the early antral follicle [5].
GCT are classified as low-grade malignancies, that are commonly detected at 
an early stage, providing a relatively favorable prognosis due to their overt clinical 
symptoms and indolent course. However, GCT have an unusual propensity for fatal 
late relapse, ~80% of women with aggressive or recurrent tumors will succumb to 
the disease [6]. At present, there are no standard methods for predicting relapse, no 
efficacious targeted therapies (aside from surgery) and no comprehensive under-
standing of the exact etiology of this disease.
2.2 Fibromas
Ovarian fibromas are the most common benign solid ovarian tumors, they repre-
sent 4% of all ovarian tumors. They are well-circumscribed masses that encompass 
spindle-shaped fibroblastic cells and abundant collagen bundles [1]. Ovarian fibro-
mas can occur at any age but usually after menopause and rarely before 30 years old. 
The most common recommended treatment is surgery [7, 8]. However, preoperative 
diagnosis is often difficult due to their solid nature and the lack of specific clinical 
signs which can result in misdiagnosis as uterine myoma [8, 9]. Ovarian fibromas 
can also be associated with hydrothorax and ascites causing Meigs’ syndrome, a rare 
condition which is usually misdiagnosed as a malignant myoma [9, 10].
2.3 Thecomas
Ovarian thecoma was first described by Loeffer and Priesel in 1932 who observed 
that these tumors resembled thecal cells, lutein cells and fibroblasts [11]. Thecoma 
accounts for 0.5% - 1% of all ovarian cancers. It occurs in mostly postmenopausal 
women with a mean age of 59 years with only 10% of patients younger than 30 years 
[12]. Thecomas can be divided into two main types; typical or luteinized, which are 
thecomas that contain steroid-type cells resembling luteinized theca and stromal 
cells [12]. The most common symptom experienced by patients is postmenopausal 
bleeding [13]. The tumors range in size from small to solid masses larger than 15cm 
[12]. Burnandt et al., found that thecoma tumors were all unilateral; the tumors are 
well circumscribed and rarely encapsulated, and are often described as yellow-tan, 
yellow-white or grayish white with no evidence of hemorrhage or necrosis [13].
2.4 Sertoli–Leydig cell tumors
Sertoli–Leydig cell tumors (SLCT) also called androblastomas and arrhenoblasto-
mas, exhibit cellular and molecular markers consistent with a dysgenesis of the ovar-
ian stromal cells, reminiscent of disorders of gonadal dysgenesis [14]. They are rare, 
accounting for less than 0.5% of all ovarian cancers [3] and can occur in women of 
all age groups, but they are more often encountered in women under 40 years of age 
[15]. Patients usually present with symptoms related to androgen excess but can also 
present with estrogenic manifestations or have an asymptomatic clinical profile. SLCT 
are typically unilateral tumors and over 97% are diagnosed at Stage 1 [3, 15]. The 
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prognosis is correlated with the degree of differentiation and stage of the tumor with 
the five year survival rate of well differentiated SLCT being ~100% [3]. In contrast 
to GCT, patients with SLCT relapse early, approximately two to three years following 
initial diagnosis [16]. Many SLCT are associated with somatic or germline mutations 
in a gene encoding an RNase III endoribonuclease, DICER1, which is involved in the 
generation of microRNAs (miRNAs) that modulate gene expression at the post-
transcriptional level [17–20]. Some studies have reported that 60% of SLCT harbor 
a DICER1 mutation [21], whereas others have reported that up to 97% of SLCT are 
DICER1 related [22]. It has been suggested that up to 100% of moderately and poorly 
differentiated SLCT have DICER1 mutations [17]. A whole exome sequencing study 
of 17 Chinese patients found somatic mutations in CDC27 (52.6%), DICER1 (21.1%) 
and MUC22 (21.1%) [23]. Germline and somatic mutations of DICER1 were higher in 
patients who were younger than 18 years than those in older patients [23].
Taking into consideration that the majority of patients presenting with SLCT are 
premenopausal with well differentiated tumors at an early stage, fertility sparing 
surgery with the removal of the affected ovary is recommended [21]. More aggres-
sive surgery and chemotherapy is considered in patients with advanced stage or 
stage 1 patients with the presence of risk factors such as intermediate and poorly 
differentiated tumors, heterologous elements, increased mitotic rate, rupture or 
spillage of the tumor or presence of metastatic tumor [16].
2.5 Gynandroblastomas
The term gynandroblastoma was coined in 1930 by Robert Meyer, who deemed 
them as an extremely rare variant of SCST comprising of both ovarian (granulosa 
cell) and testicular (Sertoli cell) histological features [24]. These low-grade hormon-
ally active tumors may also exhibit morphological evidence of stromal theca cells 
and luteinized cells resembling Leydig cells [24]. Since their first description, only a 
further 29 cases have been documented [25]. Based on the exceedingly low prevalence 
of gynandroblastomas, it appears they have a relatively benign disease course [26].
Currently, molecular insights into the histogenesis and pathogenesis of gynan-
droblastomas are lacking, but it has been postulated that they originate from a single 
progenitor cell that undergoes differentiation into both female and male elements [27]. 
This tumor type also shares many clinicopathologic features with other SCST including 
GCT and SLCT, as previously reported by Jang et al. [26]. Patients typically present 
with hormonal dysfunction with either estrogenic or androgenic symptoms [28].
The diagnostic criteria for this tumor type stipulate that either Sertoli-Leydig or 
granulosa cells should comprise at least 10% of the entire tumor mass [29]. There are 
several sex cord-stromal cell related immunohistochemical markers that exists to facili-
tate differential diagnoses including inhibin, calretinin, SF1 and CD56, however these 
are not specific to gynandroblastomas [29]. Other useful diagnostic markers include 
MART-1/melan-A [30] (specific to Sertoli-Leydig cell and steroid cell tumors), and 
the cell regulatory protein 14–3-3 sigma [28] (specific to GCT and steroid cell tumors). 
Further characterization of the molecular pathways mediating the development of gyn-
androblastomas as well as comprehensive histologic and genetic studies are required.
3. Hereditary syndromes associated with ovarian SCST
3.1 Peutz-Jeghers syndrome
Peutz-Jeghers syndrome (PJS) is associated with ovarian SCST that have histo-
logical appearance that is intermediate between GCT and SLCT [31]. The majority 
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of cases are caused by autosomal dominant germ line mutations in the STK11/LKB1 
(serine/threonine kinase 11/liver kinase B1) gene on chromosome 19p13.3 [32, 33]. 
It carries a lifetime risk of 21% [32].
LKB1 activates AMP kinase (and its 13 superfamily members), regulating 
multiple biological processes such as cell polarity, cell cycle arrest, embryo develop-
ment, apoptosis, and bioenergetics metabolism. LKB1 has become recognized as 
a critical tumor-suppressor gene that is frequently mutated in a broad spectrum 
of human cancers. As a tumor suppressor, a number of studies have shown the 
contributions of the genetic loss of LKB1 to tumorigenesis. The role of LKB1 in 
controlling cell metabolism through AMPK signaling has been widely documented. 
The LKB1-AMPK axis controls lipid and glucose metabolism, and acts as a negative 
regulator of the Warburg effect with the consequence of suppressing tumor growth 
[34]. Patients with PJS present with gastrointestinal hamartomata, polyposis and 
both benign and malignant tumors of various organs together with pigmentation 
of the lips, buccal mucosa and digits [35]. Neither loss of heterozygosity (LOH) at 
chromosome 19p13.3 nor mutations in the LKB1 gene have been observed in spo-
radic ovarian SCST [36, 37].
3.2 Ollier disease and Maffucci syndrome
Ollier disease (OD) and Maffucci syndrome (MS) are both subtypes of enchon-
dromatosis and are considered rare nonhereditary skeletal disorders [38–44], with 
an estimated prevalence of 1 in 100,000 individuals [45]. They are characterized 
by multiple enchondromas (benign cartilaginous tumors) and when accompanied 
with additional subcutaneous soft tissue hemangioma, the condition is referred to 
as MS [45, 46]. Both disorders can lead to swollen extremities, joint deformities, 
limitations in joint mobility, scoliosis, and other bone anomalies [47].
OD and MS have been linked to ovarian jGCT, the first reported case of this 
association dates to 1972 [48], and since that time, a further 16 additional cases have 
been documented [49, 50]. In 2011 Amary et al. demonstrated that >90% tumor 
patient samples with OD/MS harbored somatic missense mutations in the isocitrate 
dehydrogenase (IDH) 1 and 2 genes, 65% of which encodes a R132C amino acid 
substitution on exon 4 [51, 52]. The mutant IDH gene produces the potential ‘onco-
metabolite’ 2-hydroxyglutarate (2-HG) which induces histone hypermethylation 
[45, 51, 53]. The role of either the mutant IDH variant or 2-HG in the pathogenesis 
of OD/MS needs to be further explored, however they may represent an early post-
zygotic event which has implications in tumorigenesis [51, 54].
4. Genomic changes in ovarian SCST
As previously mentioned, studies of changes at a genomic level in ovarian SCST 
have largely been restricted to aGCT. In contrast to EOC, GCT have a relatively 
stable karyotype [55]. Cytogenetic analysis [56] and comparative genomic hybrid-
ization (CGH) [57] studies have revealed trisomy of chromosomes 12 and 14 in 
approximately one third of aGCT cases and a similar percentage of monosomy of 
chromosome 22 [56, 57]. Between 5% and 20% of aGCT are aneuploid, however, 
neither the karyotype nor ploidy provides prognostic information [56, 58–60]. 
Mutations of lesser frequency have been observed at other loci, again providing no 
prognostic significance.
In a study by Caburet et al., who applied CGH to a panel of aGCT, as well as 
collating data from a total of 94 aGCT from previous studies [61], they observed 
that a total of 64 tumors had large-scale chromosomal changes. Supernumerary 
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chromosomes 8, 9, 12 and 14 were reported, with the latter being very common 
(25 of 64). Partial or complete loss of chromosomes 1p, 13p, 16, 11 and 22, with 
monosomy 22 were also very common (36 of 64). There was co-occurrence of 
chromosomal alterations although there was only a statistically significant non-
random association for +14 with −22 and + 7 with −16q. Further, Caburet et al. 
combined transcriptomic data from a previous study [62], seeking to identify gene 
copy number changes that may reflect putative driver changes in the pathogenesis 
of aGCT [61]. Twenty genes were identified from the regions of chromosomal 
imbalance with a plausible, pathological role across nine chromosomes (1, 5, 11, 12, 
14–17, 22) including the AKT1 gene being the most frequently amplified (6 of 10 
tumors) and the nuclear receptor, rev-erbAα being the second most frequent (5 of 
10 GCT). The latter is consistent with the findings of our previous study examining 
gene expression of all 48 nuclear receptors in aGCT [63]. Caburet et al. also sought 
to identify recurrent ‘broken’ genes (the presence of a mapping breakpoint within 
the genes in two or more tumors). They observed that five genes fitted this criterion 
on 5 different chromosomes. The authors [61] speculated on the potential of these 
genes in driving the pathogenesis of GCT, while recognizing the limitation of the 
study where the correlation set comprised of only ten aGCT, nine of which were 
stage one disease [61].
For other SCSTs, reports of cytogenetic analyses are extremely scarce. A recent 
clinical case report describes three patients, from two unrelated families, with 
14q32 deletions encompassing the DICER1 locus. Two of these patients have a 
history of DICER1-related tumors, including a 15-year-old female with a SLCT 
[64]. For thecoma-fibromas, a report by Streblow et al. found that trisomy 12 is a 
non-random chromosomal abnormality, while gain of chromosome 9 and loss of 
chromosome 4 and/or 9 were features of fibromas [65]. Loss of chromosome 9 copy 
number in a subset of the fibromas analyzed is noteworthy because of the associa-
tion of ovarian fibromas and Gorlin-Goltz syndrome or nevoid basal cell carcinoma 
[66]. Gorlin-Goltz syndrome is an autosomal dominant disorder featuring distinc-
tive congenital malformations and a predisposition to a variety of benign and 
malignant neoplasms, including ovarian fibroma [67]. The gene for Gorlin-Goltz 
syndrome, PTCH1, has been localized to 9q22.3 and is characterized as a tumor sup-
pressor gene encoding for a transmembrane protein that functions as a receptor for 
sonic hedgehog [68]. LOH of one chromosome 9 homolog in three non-syndromic 
ovarian fibromas suggests a somatic role of the PTCH1 tumor suppressor gene in 
these neoplasms. Additional studies of sporadic and syndromic ovarian tumors 
of the thecoma-fibroma group using other approaches may expose an even higher 
frequency of PTCH1 loss or mutation.
4.1 Somatic genetics of jGCT
Juvenile GCT (jGCT), as with aGCT, exhibit macroscopically a mixture of solid 
and cystic components with hemorrhagic areas. Thus, it is difficult to differentiate 
jGCT and aGCT by radiologic and morphologic findings. However, their histol-
ogy differs from aGCT with a follicular or diffuse pattern of larger luteinized cells 
[69]. JGCT follicles have various sizes and shapes containing basophilic secre-
tions. The cells have rich eosinophilic and/or vacuolated cytoplasm (indicating 
luteinization) and indistinct cell borders. They contain round, hyperchromatic or 
markedly bizarre nuclei which lack the nuclear grooving characteristic of aGCT [2, 
69]. Unlike aGCT, Call- Exner bodies are not a feature of jGCT. The mitotic rate is 
high with marked nuclear atypia [2, 26]. Although the histologic appearances are 
therefore more ‘aggressive’ than for aGCT, the prognosis is generally better. The 
distinction between aGCT vs jGCT is therefore primarily based on the histology. 
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This by itself can create diagnostic dilemmas, however, these are increasingly being 
resolved by the use of the molecular markers, which are discussed below [70–72].
The gene expression profile of GCT are similar to an FSH-primed proliferat-
ing preovulatory GC [5]. FSH stimulation of GC growth is mediated by the FSH 
receptor, a G-protein-coupled, seven-transmembrane domain receptor. We and 
others have hypothesized that activation of these pathways, perhaps through 
activating mutations in these signaling molecules of the FSH signaling pathway, 
may play a role in the pathogenesis of GCT as is common in other endocrine tumors 
[2]. Despite extensive investigations, this does not appear to be the case for aGCT. 
However, mutations were found in the gsp oncogene in approximately 30% of jGCT 
[73]. The activating mutations at position 201 of the stimulatory alpha-subunit 
of the heterotrimeric G-protein (Gαs), which couples with seven-transmembrane 
domain receptors such as the FSH receptor, have been reported as somatic muta-
tions in pituitary, thyroid and adrenal tumors as well as being the inherited muta-
tion in the McCune–Albright syndrome [74]. In jGCT, the mutation is either R201C 
or R201H, and reported to be associated with a poorer prognosis [73].
In addition, it has been postulated that as the FSH receptor signals through the 
oncoprotein AKT, that mutations in this signaling pathway may contribute to the 
pathogenesis of jGCT [75]. Indeed, in one study, >60% of jGCT had an in-frame 
duplication of the plekstrin-homology domain leading to activation of AKT1. Other 
AKT1 point mutations of uncertain significance were also observed in jGCT. It was 
speculated that the resulting mutated AKT1 proteins are hyperactive with increased 
membrane association of AKT1, resulting in constitutive FOXO3 repression [75]. 
A subsequent study using transcriptomic analyses found that the changes in gene 
expression in these tumors may reflect a limited set of transcription factors altered 
by AKT1 activation [76].
4.2 Somatic genetics of aGCT
Many cancers develop from somatic mutations in driver genes that occur 
sporadically during replication or as a result of environmental factors and are 
not inherited. It is therefore important for the development of new therapeutic 
techniques to identify and consider how somatic mutations accumulate in caner 
genomes. In 2009, Shah et al. described a somatic missense mutation in the FOXL2 
gene that was found in >97% of aGCT examined [55]. Their approach utilized 
whole transcriptome paired-end RNA-sequencing (RNA-Seq) to analyze four 
aGCT. They identified a somatic missense mutation in codon 134 (402C → G) that 
results in the substitution of a highly conserved cysteine residue by tryptophan. 
Numerous studies, including our own (reviewed in Ref. [2]), have confirmed this 
finding [55]. Both heterozygosity and hemi-homozygosity of this mutation are also 
reported [2, 55]. The mutation is unique to aGCT and has not been observed in 
jGCT [2]. The rare exceptions to this rule appear either to be mixed tumors in which 
elements are in fact of GC origin or the occasional tumor which truly is ‘the excep-
tion to the rule’ [70].
The presence of the FOXL2 C134W mutation provides a clear distinction 
between jGCT and aGCT. In jGCT, FOXL2 expression is low or absent [70, 77], 
whereas in aGCT expression levels in tumors bearing the mutation are generally 
consistent with levels seen in the normal ovary [70]. FOXL2 expression in hetero-
zygous tumors appears equivalent for the wild-type and mutant FOXL2 alleles. In 
jGCT, low or absent expression of FOXL2 is associated with aggressive disease and 
carries a poor prognosis. The presence of the FOXL2 C134W mutation provides a 
molecular diagnosis of aGCT which has proven helpful in resolving the diagnosis of 
aGCT in histologically ambiguous or problematic cases [70–72].
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FOXL2 plays a fundamental and essential role in ovarian development; its 
biology has been extensively studied [78–80]. It is a member of the forkhead box 
(FOX) family of evolutionarily conserved transcription factors. The C134W muta-
tion is predicted to lie close to, but not in the DNA-binding domain [55]. Despite 
an extensive understanding of the biology of FOXL2 [78–80], the mechanisms of 
the tumorigenesis mediated by this somatic mutation in aGCT remain to be clearly 
established. In vitro evidence indicates that it impacts both steroidogenesis and 
apoptosis in GC [79]. In addition, post-translational modifications (sumoylation, 
phosphorylation, acetylation and ubiquitinylation) may also play a critical role 
in the modulation of FOXL2 function [78, 79]. Kim et al. (45) reported increased 
phosphorylation of FOXL2 as a result of the C134W mutation, subsequently leading 
its ubiquitinylation and degradation. The mutation would likely impact on critical 
protein–protein interactions of FOXL2, but these remain to be clearly elucidated. 
Caburet et al. argues that FOXL2 is a tumor suppressor gene with loss-of-function 
being associated with malignancy, as is seen in jGCT, and therefore the C134W 
mutation compromises function rather than being associated with activation or 
gain of function [78]. Conversely, others have argued that FOXL2 may act as a 
tumor suppressor gene in jGCT but the FOXL2 C134W mutation may be oncogenic 
in aGCT [80]. It’s role is likely to be more complex than a simple loss-of-function, 
as one would speculate that other inactivating mutations in the FOXL2 gene would 
have been identified in aGCT [2]. It may be reminiscent of the DICER1 mutation in 
SLCT where one facet of DICER function is selectively lost [81]. It is also curious 
that aGCT express the wild-type FOXL2 allele at equivalent levels to the mutant 
allele, a scenario which arguably affirms that the mutant FOXL2 must be ‘dominant 
negative’ if there is suppression of function.
Although the majority of aGCT are stage 1 tumors and cured by surgical resec-
tion, those who have advanced stage disease or recurrent disease carry a poor 
prognosis [2]. As the FOXL2 C134W mutation is present in the vast majority of all 
aGCT, it does not explain differences in stage or behavior. It may be, as with certain 
inherited mutations, e.g., the ret. proto-oncogene in medullary thyroid cancer [82], 
that the transition from ‘hyperplasia’ induced by the somatic mutation to frank 
malignancy requires a second independent hit. Evidence to date indicates that this 
second event may be less specific than the first. In the case of aGCT, the genomic 
changes described above may for instance reflect the ‘second hit’ that results in 
aggressive clonal expansion. The subsequent somatic mutations that presumably 
drive tumorigenesis, recurrence, aggressive behavior, transcoelomic spread and 
metastatic disease still remain to be fully elucidated.
4.3 The GCT transcriptome
Evidence provided by recent transcriptomic studies have elucidated the genes 
whose expression has been modified, in some instances, may reflect genomic 
rearrangements. Gene expression microarray was used by Benayoun et al. compar-
ing 10 aGCT with two GC samples acquired during in vitro fertilization (IVF) egg 
retrieval [62]. In principle, IVF provides a ready source of ‘normal’ tissue to be used 
as a control, however, the limitation of this control is that the GC are collected after 
IVF cycles involving a hyperstimulation regimen with gonadotropin, and hence 
the GC being partially luteinized at the time of collection [5]. Thus, these controls 
do not reflect GCs from the proliferative phase [5]. The authors identified genes 
involved in cell proliferation and a decrease in expression of genes that promote 
apoptosis [62]. Interestingly, the group showed modulation of genes that are known 
to be FOXL2 targets. Genes typically down-regulated by FOXL2 but increased in 
this context, were those associated with tumorigenicity. Conversely, genes usually 
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upregulated by FOXL2 and associated with apoptosis were down-regulated. Hence, 
it was suggested that the FOXL2 C134W mutation causes a partial loss-of-function 
suggesting it is a tumor suppressor gene. This notion is consistent with jGCT also 
lacking FOXL2 expression as previously mentioned [78].
Our laboratory has generated transcriptomic profiles between a cohort of six 
stage 1 and six stage 3 aGCT patients using a gene microarray approach to reveal 
significant differential gene expression between early and advanced stages. All of 
the aGCT samples were sequenced and also found to be heterozygous for the FOXL2 
C134W mutation [83]. A total of 16 genes were reported as highly abundant in 
the advanced aGCT, with a further 8 genes found to be more highly expressed in 
the stage 1 aGCT (p value <0.05, >2fold-change). Curiously, two genes associated 
with malignancy were found to be highly expressed in the advanced stage aGCT, a 
member of the cytokine family called CXCL14 (chemokine C-X-C-motif ligand 14), 
and a multifunctional secretion protein called MFAP5 (microfibrillar-associated 
protein 5 transcript variant 1), which were 40- and 26-fold higher, respectively. 
Of the genes whose expression was high in the stage 1 aGCT, INSL3 (insulin-like 
3 transcript variant 2) gene expression was 75-fold higher in stage 1 aGCT and 
provided robust discrimination of the two groups [83]. Whether INSL3 inhibits 
tumorigenesis or whether the diminished expression in advanced stage disease 
is simply a marker of de-differentiation of the tumor remains to be determined. 
Applying Gene Set Enrichment Analysis (GSEA) to these data sets [83] showed 
increased expression of genes on chromosome 7p15 in the stage 3 aGCT, which is 
consistent with the report of Lin et al. [57] found using CGH, gain of chromosome 
region 7p15-p21 in some aGCT samples.
4.4 The genomic landscape of GCT
Aside from the identification of the FOXL2 C134W mutation in GCT, there 
have been several studies that have aimed to identify genomic alterations through 
sequencing candidate genes and known oncogenes [2]. Genes commonly mutated 
in other malignancies such as p53, PI3K, RAS and BRAF, are not a feature in GCT, 
and thus, putative ‘second-hit’ mutations still remain to be identified. But specific. 
The approach taken by The Cancer Genome Atlas project (TCGA) where a defined 
cohort of tumors are subjected to a full suite of genomic analyses [84] has yet to be 
applied to aGCT or indeed to other ovarian SCST.
The critical challenge to be addressed as a precursor to both improved prognos-
tication (predicting recurrence) and identification of GCT-specific therapeutic tar-
gets (to address the high mortality of advanced disease) is to identify the molecular 
drivers of GCT pathogenesis beyond the aetiologic FOXL2 mutation.
In our own whole exome sequencing (WES) study, DNA from 22 fresh frozen, 
FOXL2 C134W mutation-positive GCT (14 stage 1 and 8 stage 3) was sequenced 
[85]. The analysis identified on average 64 coding and essential splice-site variants 
in each tumor, however recurrent mutations were not identified in individual genes 
or in related genes. The genes that were identified to contain truncating (stop, 
gain or frameshift) mutations, essential splice site mutations, non-synonymous 
mutations and stop/loss mutations in the stage I (970 variants) and recurrent (434 
variants) tumors, were subject to variant effect pathway analysis. The canonical 
pathways identified were linked to DNA replication and/or repair as might be 
expected in malignancy; and to signaling through the epidermal growth factor 
receptor (EGFR) family. We also identified a high frequency of a TERT promoter 
mutation (see below).
Hillman et al. [ 86] reported a comparable outcome for adult GCT subjected to 
WES [86], in a study that focused on truncating mutations of the histone lysine 
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methyltransferase gene KMT2D (also known as MLL2) as a recurrent somatic 
event. They reported these mono-allelic KMT2D-truncating variants to be more 
frequent in recurrent (23%) compared with primary (3%) GCT when an expanded 
GCT cohort was examined. KMT2D is a tumor suppressor gene that is the target of 
frequent inactivating mutations in several tumor types, including medulloblastoma 
and lymphoma. Interestingly, these mutations did not correlate with loss of protein 
as determined by immunohistochemistry (IHC). We found heterozygous KMT2D 
frameshift variants in only three (2x stage 3) of 22 GCT in our cohort [85] and Zehir 
et al. (see below) reported two frameshift variants in 11 GCT [87]. Hillman et al. 
[86] did not determine the TERT promoter mutation status of their GCT cohort.
Zehir and colleagues determined the mutational landscape in tumors from 
10,000 patients using their targeted MSK-IMPACT panel of 341 cancer associated 
genes; within this study, there were 11 FOXL2 mutation–positive GCT (two pri-
mary and nine “metastasis”) [87]. They identified mutations in 17 (5%) of the 341 
cancer-associated genes on the array in these GCT samples; in only four of these 
genes was the mutation also found in our WES study [85].
In a recent study by Pilsworth et al., the authors used a combination of whole 
genome sequencing and targeted sequencing [88], and reported a similar frequency 
of KMT2D inactivating mutations as that of the Hillman et al. study [86] (10.8% 
compared to 13.9%). The difference between the two studies however was that in 
this study, there was no association of the KMT2D mutation with recurrence [88]. 
This is consistent with another published study [89] which also showed no associa-
tion of this gene mutation with recurrent disease. The low frequency of this muta-
tion in these studies as well as our own, suggests that they may be pathogenic driver 
mutation in only a subset of aGCT. Additional inactivating mutations were also 
identified in low frequency, including the candidate tumor suppressor gene WNK2 
and a newly discovered protein called NLRC5, which has been linked to the regula-
tion of cancer immune evasion [88].
In another study, TP53 mutations were identified in 9.1% of patients, with 
higher tumor mutational burden and mitotic activity [90]. These findings suggest 
that tumors harboring TP53 mutations may be a high-grade subgroup of aGCT. It 
is noteworthy however, that other studies have not observed mutations in TP53 at 
similar frequencies [2, 88].
Indeed, the lack of overlap in the mutational variants identified in these various 
studies is curious. Also, somewhat surprising is the very limited number of recur-
rent mutations in specific genes, given that, by many criteria [83, 91], including the 
pathognomonic mutation in the FOXL2 gene [70], GCT are remarkably homog-
enous. It is conceivable that the lack of clear driver mutations may indicate that the 
key drivers are: 1) as in other cancers, including endocrine cancers, gene fusion 
events (splice-variants and translocations) which contribute the “second hit”; or 
that in ~40% of GCT, TERT mutations are an important tumorigenic event with 
perhaps loss of KMT2D in a small subset.
4.5 TERT promoter mutation
Our WES study [85] confirmed the report, from Pilsworth et al., of a telomerase 
gene (TERT) promoter mutation [92]. The TERT gene encodes the catalytic subunit 
of telomerase; TERT transcriptional regulation is the limiting step in telomerase 
activity. Elongation and/or preservation of telomere length is regarded as a hall-
mark of cancer. Two hot-spot mutations in the telomerase promoter, -124C > T and 
-146C > T are commonly found in specific cancers: melanoma, glioblastoma, blad-
der cancer and thyroid cancer, but not in common epithelial cancers, such as breast 
and prostate [87]. Our analysis using targeted PCR identified 11 of 26 (i.e., 42%) 
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of the GCT in our analysis to be heterozygous for the -124C > T TERT promoter 
mutation - a frequency that matches the above cancers [87]. 29% of the stage 1 GCT 
were heterozygous for the mutation, while 67% of the stage 3 GCT contained the 
mutation [85]. The -124C > T mutation is also present in the aGCT-derived KGN cell 
line [85]. There are in vitro data that the two promoter mutations are not equivalent 
[93], suggesting that in GCT there is a tumorigenic advantage only for the -124C > T 
promoter mutation.
Increased telomerase activity appears also to be associated with cell proliferation 
independent of telomere lengthening [94]. TERT has been reported to interact with 
major oncogenic signaling pathways including c-MYC, NFκB, and Wnt/β-catenin. 
Of these, activation of NFκB signaling has been reported in the KGN cell line [91, 
95] and p65 nuclear localization has been reported in GCT [96], although previous 
studies [85, 86, 88, 90] have not identified mutations in these pathways.
It has been noted that melanoma, glioma, and papillary thyroid and bladder 
carcinomas, all of which have a high frequency of TERT promoter mutations, are 
characterized by activation through BRAF or EGFR mutation of the MAPK signal-
ing pathway [97]. This association is intriguing given this high frequency of the 
TERT promoter mutation in GCT and the suggestion from pathway analysis of the 
WES study linking one of the canonical pathways to signaling through the EGFR 
family [85]. The high incidence of the TERT promoter mutation in GCT, together 
with the correlation of the presence of this mutation with stage, suggests that the 
presence of the TERT promoter mutation, as in other tumors, may be of prognostic 
and/or pathogenic significance, and acquired during tumor progression after the 
initial FOXL2 driver mutation.
4.6 DICER1 syndrome
DICER1 syndrome is a rare inherited disorder that increases the risk of a variety 
of cancerous and non-cancerous tumors that occur in the lungs, kidneys, ovaries 
and thyroid. DICER1 syndrome results from germ-line mutations in the DICER1 
gene, located on chromosome 14, position q32.13, encodes an RNase III endoribo-
nuclease which plays a critical role in processing micro(mi)RNA to their mature 
forms. DICER1 contains two highly conserved RNase III domains (RNaseIIIa and 
RNaseIIIb) which forms a catalytic dimer, creating a single processing center for 
dsRNA cleavage, with each RNase III domain cleaving one strand of the dsRNA 
resulting in miRNA named by their prime end origin (3p/5p miRNA) [98]. Germ 
line and somatic mutations in the DICER1 gene have been described in ovarian 
SCST, predominantly for SLCT. DICER1 mutations were initially reported to 
cause familial pleuro-pulmonary blastoma, but have been subsequently found in a 
variety of tumors, including ovarian SLCT and in association with benign thyroid 
pathologies [20]. The mutations occur in approximately 60% of ovarian SLCT of 
which 80% are the p.E1705K mutation [19, 20]. DICER1 mutations are also seen in 
gynandroblastomas. They have not been associated with GCT or, testicular stromal 
tumors [19, 20, 72]. The functional consequence of DICER1 mutations is there 
is a bias caused by the mutated DICER toward processing of the RNasIIIa strand 
of the miRNA duplex [19, 81]. Thus, there is a selective reduction in RNaseIIIb 
activity and retention of RNaseIIIa activity, resulting in an excess of 3p-miRNA 
and a depletion of 5p-miRNA [19, 81, 98]. One copy of the altered gene is suf-
ficient to cause an increased risk of developing tumors. Although a mutation in the 
DICER1 gene can infer an increased chance of developing SLCT, many individuals 
who carry a mutation in the DICER1gene do not necessarily develop tumors [99]. 
The therapeutic or diagnostic value of these mutations for SLCT warrants further 
investigations.
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5.The ‘miRNA-ome’ and other non-coding RNAs
A pathogenic role for miRNA in SCST can be indicated by the identification of 
aberrant miRNA processing in SLCT and gynandroblastomas. However, studies of 
the ‘miRNA-ome’ have been limited. Rosario et al. profiled miRNA expression and 
regulation in the KGN and COV434 cell lines [100]. They observed that COV434 
cells preferentially expressed miR-17 family members whereas the KGN cells 
preferentially expressed members of the let-7 miRNA gene family [100]. There 
has not however, been any systematic studies in GCT or, to our knowledge, for 
other SCST.
Long non-coding (lnc) RNA’s have also been implicated in oncogenesis [101]. 
Evidence indicates that lncRNA can produce short peptides from small open read-
ing frames (smORFs) which can regulate biological processes [102]. The status of 
both lncRNA, and indeed, smORFs remains to be investigated in SCST.
6. GCT-derived cell lines
The human KGN and COV434 cell lines, have been thought to be derived from 
GCT, and are extensively used in studies of GCT as well as to model normal GC 
function. Both cell lines exhibit some features that are reminiscent of normal pro-
liferating GC, including a functional FSH receptor and aromatase activity. Jamieson 
et al. analyzed the FOXL2 status of both cell lines [70], concluding the COV434 cells 
lack FOXL2 expression and indeed the C134W mutation, lending to the assumption 
that they are derived from a jGCT [70]. In contrast, the KGN cell line (established 
from a metastatic aGCT), expresses FOXL2 and is heterozygous for the FOXL2 
mutation, which is consistent with it being derived from an aGCT [70]. Both cell 
lines were established from patients with advanced aggressive disease.
Both KGN and COV434 cell lines are notable for constitutive activity of the 
NFκB and Braf/ERK signaling pathways [91, 95, 103]. A molecular study using a 
transcriptomic approach conducted by Rosario et al. was used to identify potential 
targets of FOXL2 in KGN and COV434 cells [104]. They observed that many of the 
genes regulated by wild-type FOXL2 were also regulated by the mutant FOXL2, 
notably genes involved in the transforming growth factor-beta (TGF-β) signaling 
pathway. Their analysis also highlighted the significant differences between the 
COV434 and the KGN gene-expression profiles [104]. In our transcriptomic analysis 
of aGCT [83], we observed over 3000 entities that differed greater than twofold 
(p value of <0.05) when 12 aGCT were compared with the KGN cells. This was in 
stark contrast to only 24 differentially expressed genes observed when comparing 
the stages 1 and 3 aGCT. Thus, although the two cell lines are valuable tools in the 
analysis of signaling pathways in the context of both GCT and indeed GC, they do 
not assist in the genomic and/or genetic analysis of aGCT.
The classification of COV434 as a GCT-derived cell line has been questioned. 
Recent studies show that this cell line was likely derived from a small-cell carcinoma 
of the ovary hypercalcemic-type (SCCOHT) [105–107]. The cell of origin of these 
tumors is unknown, with reports postulating they are likely derived from the germ 
cells [108]. Recent advances in molecular genetics have indicated that SCCOHT 
can be regarded as an ovarian malignant teratoid/rhabdoid tumor (MRT) [109]. 
SCCOHT are characterized by the loss of both SMARCA2 and SMARCA4, which are 
also not expressed in COV434 cells [105, 107]. Moreover, the lack of expression of 
RUNX2 and high expression of RUNX3 in COV434 suggests that these cells do not 
represent primary jGCT [106]. Noticeably, the study of Karnezis et al. indicates that 
COV434 cell line has all morphological, immunohistochemical, genetic and clinical 
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characteristics of SCCOHT [107]. They also noted that the level of serum calcium in 
mice increases when transplanting with COV434 [107].
7. Animal models of ovarian SCST
A number of mouse models in which GCT arise have been reported, however 
none truly recapitulate the human disease [2, 110]. Liu et al. have described the 
development of GCT in mice with conditional inactivation of FOXO1/3 in GC 
[110]. The development of these tumors was accelerated with perturbation of the 
multi-functional tumor suppressor gene PTEN. An examination of PTEN and 
FOXO1/3 expression in five primary human aGCT samples found low expression 
for each [110], leading them to conclude that this mouse model, in contrast to 
others, shares some characteristics with aGCT. Arguably however, involvement of 
PTEN in the model, is more consistent with activation of PI3K/AKT which is more 
of a feature of jGCT. It should be noted that neither mutation, over-expression 
of PIK3CA or PIK3R1, nor loss of expression of PTEN, has been reported in 
aGCT [111]. Work from Lague et al. has provided evidence in mouse models for 
a synergistic effect of the Wnt/β-catenin and PI3K/AKT pathways in the forma-
tion of GCT, which is of interest given the potential role for AKT1 mutations in 
jGCT [112]. Wnt/β-catenin signaling pathway has well established roles in ovarian 
development and in GC function [2]. Although dysregulation of Wnt/β-catenin 
signaling has been identified in many human cancers, there is no evidence for 
activation of this pathway in human GCT [113, 114], which contrasts to equine 
GCT where there is clear evidence of Wnt/β-catenin signaling activation [113]. 
Increased ovarian R-spondin1 signaling, which modulates Wnt signaling is associ-
ated with GC-like tumors [115]. Gao et al. targeted expression of a constitutively 
activated TGF-β receptor to GC and found GCT that were associated with elevated 
inhibin and estrogen levels [116] as is seen in human GCT which perhaps more 
closely recapitulates the clinical situation than earlier models in which inhibin gene 
deletion resulted in GCT (see below) [117]. One of the downstream consequences 
of this activation is again, increased AKT signaling. The knockout of the inhibin α 
subunit (shared by both inhibin A and B) causes the development of SCST in mice 
of both sexes as early as four weeks [117–119]. In these inhibin α null mice, FSH 
levels has increased by two to three fold which correspond to inhibin’s physiologi-
cal function to suppress FSH [118]. However, a double knockout of inhibin α and 
FSH unexpectedly showed development of gonadal tumors in the mice; the tumors 
developed after 12 weeks of age [117–121]. The inhibin α knockout led to increas-
ing levels of activin which induce the activation of SMAD2/3 signaling pathway in 
GC [117, 121]. The study of Madh3 (SMAD3-null) and inhibin α double knockout 
mice demonstrated slow progression of tumor growth; SMAD 3 is thus important 
for tumor progression [121–123].
8. Treatment strategies for SCST
The uncommon nature of SCST limits the ability to develop targeted therapies 
and evaluate them in well-powered clinical trials. A recent search of clinicaltrials.
gov showed only 11 trials that are either active of recruiting involving SCSTs, with 
only five completed results described. The application of new sequencing technolo-
gies may lead to the discovery of novel driver genes that lead to these rare ovarian 
cancers. However, as discussed above, these have so far been elusive from the 
limited studies performed to date.
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8.1 Treatment of GCT
Surgical treatment is the mainstay for peri-and postmenopausal women diag-
nosed with aGCT, with total abdominal hysterectomy (TAH), bilateral salpingo-
oophorectomy (BSO) and full staging surgery thought to be the most appropriate 
initial treatment [124]. Randomized trials of adjuvant chemotherapy are not 
available, and for patients with poor prognosis, adjuvant platinum-based chemo-
therapy is generally considered either alone or in combination with doxorubicin 
and cyclophosphamide (CAP) [125, 126], vinblastine and bleomycin (PVB) [127], 
etoposide or etoposide and bleomycin (BEP) [128, 129]. The use of these treatment 
regimens is often based on those employed for epithelial ovarian cancer and in the 
main have proven to be of limited benefit [130].
Hormone treatment has shown promise in the treatment of advanced GCT 
based on their frequent estrogen dependence [2, 131, 132]. A systematic review of 
hormonal therapy for GCT revealed a pooled response rate of 71% and aromatase 
inhibitors (AI) were identified by far the most effective agents [131]. In a more 
recent study, the use of AI in 25 cases with known outcomes, the response rate to 
AIs was 48% (12/25) and the clinical benefit rate was 76% (19/25) [132]. Although 
these numbers are limited, they indicate the use of AIs as a potential alternative 
to chemotherapy, although the mechanisms involved in GCT sensitivity to AIs 
remains undefined. Other forms of hormone therapy have also previously shown 
promise with reports of prolonged remission (14–42 months) documented in 
patients with extensive disease treated with high doses of medroxyprogestroneac-
etate [133, 134].
The expression of vascular endothelial growth factor (VEGF) appears per-
sistent with most GCT, with almost all tumors (93%) showing positive VEGF 
immunostaining in one study [135, 136]. The use of the anti-VEGF-A monoclonal 
antibody, bevacizumab, was shown to cause apoptosis in GCT-derived cells in vitro 
[136]. Extending this to a small retrospective study showed promising activity 
with bevacizumab in 8 women with recurrent GCT [137]. There was one complete 
response in an overall response rate of 38%, with the clinical benefit rate being 63%. 
Bevacizumab is also effective in treating ascites in recurrent GCT, reflecting the 
role of tumor-derived VEGF in the formation of cancer-related ascites [138]. This 
led to a prospective phase II clinical trial of bevacizumab in relapsed aGCT which 
reported a 16.7% response rate and median progression free survival of 9.3 months 
(95% CI 4.1–15 months) in the 36 patients recruited [139].
Tyrosine kinases are well recognized as being fundamental to many growth fac-
tor signaling pathways in both normal and malignant cells. The advent of specific 
inhibitors of tyrosine kinases (TKI) has focused attention on the potential of TK as 
therapeutic targets. In view of the evidence of activation of cell signaling in GCT 
and a case report of a recurrent GCT responding to the TKI, imatinib (Gleevec), 
our group demonstrated that the GCT-derived cell lines were inhibited by imatinib 
and indeed by the newer more potent analog, nilotinib, but at concentrations higher 
than those required for the targeted receptor kinases [140]. The AP-1 signaling 
pathway is also constitutively activated in GCT [95]. We tested a TKI, sorafenib 
(Nexavar, Bayer), which has high affinity for Raf-1 and Braf, in addition to the 
above-mentioned TK, and found that this TKI elicits a dose dependent inhibi-
tion of both cellular proliferation and viability in both cell lines at concentrations 
equivalent to that seen in other systems [141]. A commercially available Raf-1 
kinase inhibitor was also examined and found to have no effect on cell proliferation 
and viability in both cell lines, thus implicating Braf in the activated AP-1 signaling 
[141]. Based on these data, clinical investigation of sorafenib or possibly a more 
potent BRAF inhibitor, such as vemurafenib or dabrafenib, may be warranted.
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Little is known about the immune response in SCST. Expression of the immune 
checkpoint protein, programmed death-ligand 1 (PD-L1) has been reported only 
in abstract form, and present in ~75% of SCSTs [142], however, immunotherapy 
has not been reported in a clinical trial for these tumors. A more recent study by 
Pierini et al., suggests that tumor infiltrating lymphocytes (TILS) are the main 
immune population in GCT [143], and that after ex vivo expansion of TILS isolated 
from 11 GCT patients, showed they vigorously reacted against autologous tumors 
(100% patients) and against FOXL2 peptides (57.1% of patients). This suggests that 
FOXL2 immune targeting can produce substantial long-term clinical benefits and 
lay a foundation for future trials testing immunotherapeutic approaches toward 
GCT [143].
Based on several studies, there is also the potential for more targeted therapies 
that arise from identifying the molecular mechanisms that contribute to the 
pathogenesis of GCT. The NFκB signaling pathway is often involved in cancer 
development; activated NFκB increases the expression of genes involved in cell 
proliferation, metastasis, angiogenesis and anti-apoptosis [144]. Apoptosis is 
directed by activated caspases. The Inhibitors of Apoptosis (IAP) proteins sup-
press apoptosis through the inhibition of the caspases. The cellular IAP1 (cIAP1 
or BIRC2), cellular IAP2 (cIAP2 or BIRC3) and X chromosome-linked IAP (XIAP 
or BIRC4) are the main IAPs with known roles in apoptosis and cancer [145–147]. 
XIAP is the best characterized and also the most potent caspase inhibitor, blocking 
both intrinsic and extrinsic apoptotic signals by directly inhibiting caspases-3, −7 
and − 923. cIAP1 and cIAP2 have less potent roles in opposing these pathways as 
they do not directly bind caspases, however they can indirectly cause caspase cleav-
age [145–147]. Inhibition of cIAPs and XIAP causes cells to become more receptive 
to both intra- and extracellular apoptotic signals [148]. XIAP is predominantly 
regulated by an endogenous mitochondrial protein called second mitochondria-
derived activator of caspases (Smac), which is released during apoptosis, and 
interacts with XIAP through conserved amino acid residues in the BIR3 domain of 
XIAP to antagonize XIAP-mediated caspase inhibition [149].
Due to its elevated expression and prominent ability to inhibit cell death, XIAP 
is an attractive therapeutic target for anti-cancer treatment [145–147]. Smac-
mimetics (SM) bind directly to XIAP with high affinity to prevent caspase binding, 
thus neutralizing XIAPs pro-oncogenic function. A number of Smac-mimetics 
have demonstrated good anti-cancer activity in preclinical studies, and several 
have already passed primary phase clinical trials, suggesting that these compounds 
are well tolerated [146]. Though XIAP, IAP or pan-IAP inhibitors have shown 
some efficacy as single agents, the majority of studies have shown more promise 
when used in a rational drug combination strategy [146]. We have shown in vitro 
and using GCT explants in culture, that targeting XIAP as a combination therapy 
with activation of the peroxisome proliferator-activated receptor-gamma protein 
(PPARγ) provides a novel and specific therapeutic strategy for GCT [150, 151]. It 
remains to be determined the effectiveness of this combination approach in in vivo 
studies.
9. Conclusions
Recent genetic discoveries have provided profound insights into the molecular 
pathogenesis of ovarian SCST. As with other uncommon tumor types, insight from 
research of SCST will potentially be prismatic; that is, it will help clarify molecular 
mechanisms involved in oncogenesis. In SLCT, the discovery of DICER1 mutations 
highlight both the complexity and asymmetry of miRNA processing, while also 
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supporting the potential for ‘non-coding’ RNA in playing a critical role in malignant 
cancers. In the case of jGCT, the presence of the recurring mutations in the gsp 
oncogene and in AKT1, highlights the critical role of the cyclic AMP/protein kinase 
A and PI3kinase/AKT signaling pathways in hormone-mediated cell prolifera-
tion, as well as when constitutively activated, in malignancy. We and others have 
demonstrated that the FOXL2 C134W mutation found in aGCT would appear to 
be pathognomonic, however, the precise mechanism of this mutation still remains 
some-what controversial, despite being discovered over a decade ago. For other 
SCST, gene alterations and mutations appear restricted to their syndromic context. 
The above findings have provided insights into the biology of the respective genes 
involved in the pathogenesis, and to the role they play in sex-cord stromal cell 
development. The prognostic significance and therapeutic potential of these find-
ings are of critical interest to those women afflicted with these malignancies. What 
is also very clear is that these tumors are uniquely different to the EOC, which in the 
context of the age of ‘precision’ medicine, each tumor type must be treated with a 
tumor-, and/or a mutation-specific approach. As an example, for the more common 
aGCT tumor type, advanced stage disease carries a poor prognosis, and yet, options 
beyond the FOXL2 mutation are still to be identified. Targeting the FOXL2 mutation 
is likely to be difficult. Hence further targets are potentially needed in order to treat 
this disease with a more targeted approach. It is clear that other genetic or genomic 
changes must determine late recurrence or an advanced stage. With a multi-omics 
approach involving the application of whole genome sequencing, whole-exome 
sequencing, RNA-seq as well as interrogation of the miRNA-ome, critical driver 
mutations for GCT or the other SCST will likely be identified, with the hope that 
these are ‘actionable’ mutations, and thus leading to more precision targeted 
therapy.
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